Active, not recruitingPhase 2NCT04663308
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Studying Primary sclerosing cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Intervention
- Volixibat(drug)
- Enrollment
- 182 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Southern California Research Center, Coronado, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- University of California, Davis, Sacramento, California, United States
- California Pacific Medical Center Research Institute, San Francisco, California, United States
- University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Florida Research Institute, Lakewood Rch, Florida, United States
- University of Miami - Schiff Center for Liver Diseases, Miami, Florida, United States
- Tampa General Hospital, Tampa, Florida, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Southern Therapy and Advanced Research LLC, Jackson, Mississippi, United States
- Northwell Health, Manhasset, New York, United States
- New York University Langone Health, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04663308 on ClinicalTrials.govOther trials for Primary sclerosing cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07229911A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)Takeda
- RECRUITINGPHASE2NCT06699121A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSCLISCure Biosciences
- RECRUITINGPHASE2NCT06905054Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationMayo Clinic
- RECRUITINGNANCT06865924Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing CholangitisFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06297993Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)PSC Partners Seeking a Cure
- RECRUITINGNANCT06351696The Effects of Bromelain Supplement in Patients With Ulcerative ColitisNational Nutrition and Food Technology Institute
- RECRUITINGPHASE2NCT06286709FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitisUniversity of Birmingham
- RECRUITINGEARLY PHASE1NCT06197308Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSCUniversity of Minnesota